It is mainly based on immunomagnetic technologies relying on antibodies against the epithelial cell adhesion molecule (EpCAM) such as in the CellSearch system, which is the only FDA-approved technology to enrich CTCs from blood of breast, prostate, colorectal, or lung cancer patients [7]. The gene discussed is EPCAM; the disease is lung cancer.